These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33621083)

  • 1. Biosynthetic Interrogation of Soil Metagenomes Reveals Metamarin, an Uncommon Cyclomarin Congener with Activity against
    Li L; MacIntyre LW; Ali T; Russo R; Koirala B; Hernandez Y; Brady SF
    J Nat Prod; 2021 Apr; 84(4):1056-1066. PubMed ID: 33621083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Resolution Structure of ClpC1-Rufomycin and Ligand Binding Studies Provide a Framework to Design and Optimize Anti-Tuberculosis Leads.
    Wolf NM; Lee H; Choules MP; Pauli GF; Phansalkar R; Anderson JR; Gao W; Ren J; Santarsiero BD; Lee H; Cheng J; Jin YY; Ho NA; Duc NM; Suh JW; Abad-Zapatero C; Cho S
    ACS Infect Dis; 2019 Jun; 5(6):829-840. PubMed ID: 30990022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus.
    Choules MP; Wolf NM; Lee H; Anderson JR; Grzelak EM; Wang Y; Ma R; Gao W; McAlpine JB; Jin YY; Cheng J; Lee H; Suh JW; Duc NM; Paik S; Choe JH; Jo EK; Chang CL; Lee JS; Jaki BU; Pauli GF; Franzblau SG; Cho S
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antibiotic cyclomarin blocks arginine-phosphate-induced millisecond dynamics in the N-terminal domain of ClpC1 from
    Weinhäupl K; Brennich M; Kazmaier U; Lelievre J; Ballell L; Goldberg A; Schanda P; Fraga H
    J Biol Chem; 2018 Jun; 293(22):8379-8393. PubMed ID: 29632076
    [No Abstract]   [Full Text] [Related]  

  • 5. The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease.
    Schmitt EK; Riwanto M; Sambandamurthy V; Roggo S; Miault C; Zwingelstein C; Krastel P; Noble C; Beer D; Rao SP; Au M; Niyomrattanakit P; Lim V; Zheng J; Jeffery D; Pethe K; Camacho LR
    Angew Chem Int Ed Engl; 2011 Jun; 50(26):5889-91. PubMed ID: 21563281
    [No Abstract]   [Full Text] [Related]  

  • 6. Antimycobacterial Rufomycin Analogues from
    Zhou B; Shetye G; Yu Y; Santarsiero BD; Klein LL; Abad-Zapatero C; Wolf NM; Cheng J; Jin Y; Lee H; Suh JW; Lee H; Bisson J; McAlpine JB; Chen SN; Cho SH; Franzblau SG; Pauli GF
    J Nat Prod; 2020 Mar; 83(3):657-667. PubMed ID: 32031795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A New Screen for Tuberculosis Drug Candidates Utilizing a Luciferase-Expressing Recombinant Mycobacterium bovis Bacillus Calmette-Guéren.
    Ozeki Y; Igarashi M; Doe M; Tamaru A; Kinoshita N; Ogura Y; Iwamoto T; Sawa R; Umekita M; Enany S; Nishiuchi Y; Osada-Oka M; Hayashi T; Niki M; Tateishi Y; Hatano M; Matsumoto S
    PLoS One; 2015; 10(11):e0141658. PubMed ID: 26571296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of the N-terminal domain of ClpC1 in complex with the antituberculosis natural product ecumicin reveals unique binding interactions.
    Wolf NM; Lee H; Zagal D; Nam JW; Oh DC; Lee H; Suh JW; Pauli GF; Cho S; Abad-Zapatero C
    Acta Crystallogr D Struct Biol; 2020 May; 76(Pt 5):458-471. PubMed ID: 32355042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of mycobacterial inhibition by cyclomarin A.
    Vasudevan D; Rao SP; Noble CG
    J Biol Chem; 2013 Oct; 288(43):30883-91. PubMed ID: 24022489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of the drug target ClpC1 unfoldase in action provides insights on antibiotic mechanism of action.
    Weinhäupl K; Gragera M; Bueno-Carrasco MT; Arranz R; Krandor O; Akopian T; Soares R; Rubin E; Felix J; Fraga H
    J Biol Chem; 2022 Nov; 298(11):102553. PubMed ID: 36208775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1.
    Lee H; Suh JW
    J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):205-12. PubMed ID: 26586403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The unfoldase ClpC1 of
    Lunge A; Gupta R; Choudhary E; Agarwal N
    J Biol Chem; 2020 Jul; 295(28):9455-9473. PubMed ID: 32409584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial peptide CyclomarinA creates toxicity by deregulating the Mycobacterium tuberculosis ClpC1-ClpP1P2 protease.
    Taylor G; Frommherz Y; Katikaridis P; Layer D; Sinning I; Carroni M; Weber-Ban E; Mogk A
    J Biol Chem; 2022 Aug; 298(8):102202. PubMed ID: 35768046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NRPS substrate promiscuity leads to more potent antitubercular sansanmycin analogues.
    Xie Y; Cai Q; Ren H; Wang L; Xu H; Hong B; Wu L; Chen R
    J Nat Prod; 2014 Jul; 77(7):1744-8. PubMed ID: 24964393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo.
    Gao W; Kim JY; Anderson JR; Akopian T; Hong S; Jin YY; Kandror O; Kim JW; Lee IA; Lee SY; McAlpine JB; Mulugeta S; Sunoqrot S; Wang Y; Yang SH; Yoon TM; Goldberg AL; Pauli GF; Suh JW; Franzblau SG; Cho S
    Antimicrob Agents Chemother; 2015 Feb; 59(2):880-9. PubMed ID: 25421483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
    Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gift from Nature: Cyclomarin A Kills Mycobacteria and Malaria Parasites by Distinct Modes of Action.
    Bürstner N; Roggo S; Ostermann N; Blank J; Delmas C; Freuler F; Gerhartz B; Hinniger A; Hoepfner D; Liechty B; Mihalic M; Murphy J; Pistorius D; Rottmann M; Thomas JR; Schirle M; Schmitt EK
    Chembiochem; 2015 Nov; 16(17):2433-6. PubMed ID: 26472355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cadasides, Calcium-Dependent Acidic Lipopeptides from the Soil Metagenome That Are Active against Multidrug-Resistant Bacteria.
    Wu C; Shang Z; Lemetre C; Ternei MA; Brady SF
    J Am Chem Soc; 2019 Mar; 141(9):3910-3919. PubMed ID: 30735616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.